What is Zacks Research's Estimate for NKTR Q2 Earnings?

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at Zacks Research cut their Q2 2025 EPS estimates for shares of Nektar Therapeutics in a report released on Monday, June 30th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of ($2.83) per share for the quarter, down from their previous estimate of ($0.19). The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics' Q3 2025 earnings at ($2.85) EPS, Q4 2025 earnings at ($2.86) EPS, Q1 2026 earnings at ($3.03) EPS, Q2 2026 earnings at ($3.59) EPS, Q3 2026 earnings at ($4.00) EPS, Q4 2026 earnings at ($4.10) EPS, FY2026 earnings at ($14.72) EPS, Q1 2027 earnings at ($3.92) EPS, Q2 2027 earnings at ($4.46) EPS and FY2027 earnings at ($18.57) EPS.

A number of other equities analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Wednesday, May 14th. BTIG Research boosted their target price on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, June 24th. William Blair reaffirmed a "market perform" rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. HC Wainwright boosted their target price on shares of Nektar Therapeutics to $120.00 and gave the stock a "buy" rating in a research note on Tuesday, June 24th. Finally, Oppenheimer raised shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $90.00 target price for the company in a research note on Friday, March 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Nektar Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $84.17.

Nektar Therapeutics Stock Down 3.4%

NASDAQ:NKTR traded down $0.88 on Wednesday, reaching $24.65. The stock had a trading volume of 994,109 shares, compared to its average volume of 477,427. The company has a market capitalization of $305.91 million, a P/E ratio of -2.57 and a beta of 0.94. Nektar Therapeutics has a 1-year low of $6.48 and a 1-year high of $37.38. The stock has a fifty day moving average price of $12.97 and a 200-day moving average price of $12.55.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) EPS for the quarter, missing analysts' consensus estimates of ($2.70) by ($0.60). The firm had revenue of $10.46 million during the quarter, compared to analyst estimates of $15.61 million. Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. During the same quarter last year, the firm earned ($2.70) earnings per share.

Institutional Investors Weigh In On Nektar Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC bought a new stake in shares of Nektar Therapeutics during the fourth quarter worth approximately $130,000. Wellington Management Group LLP increased its stake in Nektar Therapeutics by 10.4% in the fourth quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company's stock valued at $486,000 after purchasing an additional 49,319 shares in the last quarter. D. E. Shaw & Co. Inc. increased its stake in Nektar Therapeutics by 267.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 175,193 shares of the biopharmaceutical company's stock valued at $163,000 after purchasing an additional 127,459 shares in the last quarter. Rhumbline Advisers increased its stake in Nektar Therapeutics by 23.3% in the first quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company's stock valued at $151,000 after purchasing an additional 41,948 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Nektar Therapeutics by 32.8% in the fourth quarter. Ameriprise Financial Inc. now owns 373,948 shares of the biopharmaceutical company's stock valued at $348,000 after purchasing an additional 92,346 shares in the last quarter. 75.88% of the stock is owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.